通心络胶囊联合瑞舒伐他汀钙治疗冠心病心绞痛的临床效果及对血清ET-1、NO、cTnI、vWF水平的影响

目的 探讨通心络胶囊联合瑞舒伐他汀钙治疗冠心病心绞痛的临床效果及对血清ET-1、NO、cTnI、vWF水平的影响.方法 回顾性选取本院2018年1月至2020年1月收治的100例冠心病心绞痛患者,依据治疗方法将其分为联合治疗组(50例,瑞舒伐他汀钙联合通心络胶囊治疗)和单独治疗组(50例,瑞舒伐他汀钙单独治疗).比较两...

Clinical effect of Tongxinluo capsule combined with rosuvastatin calcium in the treatment of coronary heart disease and angina pectoris and its influences on serum ET-1,NO,cTnI and vWF levels

Objective To investigate the clinical effect of Tongxinluo capsule combined with rosuvastatin calcium in the treatment of coronary heart disease and angina pectoris and its influences on serum ET-1,NO,cTnI and vWF levels.Methods A total of 100 patients with coronary heart disease and angina pectoris admitted in our hospital from January 2018 to January 2020 were selected retrospectively,and the patients were divided into combined treatment group(50 cases,rosuvastatin calcium combined with Tongxinluo capsule treatment)and single treatment group(50 cases,rosuvastatin calcium alone treatment)according to the treatment method.The therapeutic effect,serum ET-1,NO,cTnI,vWF levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the combined treatment group was 92.0%,which was significantly higher than 76.0%in the single treatment group(P<0.05).After treatment,the serum ET-1,cTnI and vWF levels in the two groups decreased,and the serum NO level increased,and those in the combined treatment group were significantly better than the single treatment group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Tongxinluo capsule combined with rosuvastatin calcium in the treatment of coronary heart disease and angina pectoris has a significant clinical effect,it can reduce the serum ET-1,cTnI,vWF levels of patients,improve the serum NO level,and will not increase the adverse reactions,which is worthy of clinical promotion and application.